Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

Breast Cancer Research and Treatment

Volumn 122, Issue 3, 2010, Pages 627-636

  Lipton, Allan ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Anticancer; Bisphosphonates; Bone loss; Breast cancer; Zoledronic acid

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT;

ANTINEOPLASTIC ACTIVITY; BONE ATROPHY; BONE DENSITY; BONE MARROW; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BONE NEOPLASMS; BREAST NEOPLASMS; DRUG COMBINATION; DRUG EFFECTS; FEMALE; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; TREATMENT OUTCOME;

EID: 77955557682     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0935-7     Document Type: Review

References (63)

1. Garcia M, Jemal A, Ward EM et al (2007) Global cancer facts & figures, 2007. American Cancer Society, Atlanta
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
3. P Hadji 2009 Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Crit Rev Oncol Hematol 69 73 82 10.1016/j.critrevonc.2008.07.013 18757208
4. ES Siris Y-T Chen TA Abbott, et al. 2004 Bone mineral density thresholds for pharmacological intervention to prevent fractures Arch Intern Med 164 1108 1112 10.1001/archinte.164.10.1108 15159268 (Pubitemid 38668990)
5. D Bliuc ND Nguyen VE Milch, et al. 2009 Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 513 521 10.1001/jama.2009.50 1:CAS:528:DC%2BD1MXhtlyqs7Y%3D 19190316
6. WJ Boyle WS Simonet DL Lacey 2003 Osteoclast differentiation and activation Nature 423 337 342 10.1038/nature01658 1:CAS:528:DC%2BD3sXjs1ynu7g%3D 12748652 (Pubitemid 40852708)
7. TJ Powles T Hickish JA Kanis, et al. 1996 Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women J Clin Oncol 14 78 84 1:CAS:528:DyaK28XhtVOjt74%3D 8558225
8. A Sverrisdottir T Fornander H Jacobsson, et al. 2004 Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy J Clin Oncol 22 3694 3699 10.1200/JCO.2004.08.148 1:STN:280:DC%2BD2cvls1Cqsw%3D%3D 15365065 (Pubitemid 41095208)
9. L Vehmanen I Elomaa C Blomqvist, et al. 2006 Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status J Clin Oncol 24 675 680 10.1200/JCO.2005.02.3515 1:CAS:528:DC%2BD28XhvFKhtLk%3D 16446340 (Pubitemid 46630433)
10. M Gnant B Mlineritsch G Luschin-Ebengreuth, et al. 2008 Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol 9 840 849 10.1016/S1470-2045(08)70204-3 1:CAS:528: DC%2BD1cXhtVOiurnL 18718815
11. J Pfeilschifter IJ Diel 2000 Osteoporosis due to cancer treatment: pathogenesis and management J Clin Oncol 18 1570 1593 1:STN:280: DC%2BD3c3gtVGisw%3D%3D 10735906
12. CL Shapiro J Manola M Leboff 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer J Clin Oncol 19 3306 3311 1:CAS:528:DC%2BD3MXlvVamsr4%3D 11454877
13. J Bines DM Oleske MA Cobleigh 1996 Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer J Clin Oncol 14 1718 1729 1:CAS:528:DyaK28XjtFKitro%3D 8622093
14. KK Swenson MJ Nissen E Anderson, et al. 2009 Effects of exercise vs. bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy J Support Oncol 7 101 107 1:CAS:528:DC%2BD1MXmvFaqtbw%3D 19507458
15. O Bock D Felsenberg 2008 Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice Clin Interv Aging 3 279 297 1:CAS:528:DC%2BD1cXpt1WqtLk%3D 18686751
16. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474
17. P Hadji N Bundred 2007 Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer Semin Oncol 34 suppl 4 S4 S10 10.1053/j.seminoncol.2007.10.005 1:CAS:528:DC%2BD1cXht1ejsrk%3D 18068489
18. DL Hershman DJ McMahon KD Crew, et al. 2008 Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer J Clin Oncol 26 4739 4745 10.1200/JCO.2008.16.4707 1:CAS:528:DC%2BD1cXhtlSqsb7N 18711172
19. A Brufsky N Bundred R Coleman, et al. 2008 Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole Oncologist 13 503 514 10.1634/theoncologist.2007-0206 1:CAS:528: DC%2BD1cXotFait70%3D 18515735 (Pubitemid 351872868)
20. Frassoldati A, Brufsky A, Bundred N, et al (2008) The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24-month integrated follow-up of the Z-FAST and ZO-FAST trials [poster]. Presented at: 33rd Congress of the European Society for Medical Oncology, Stockholm, Sweden, 12-16 September 2008 (Abstr 185PD)
21. M Gnant B Mlineritsch W Schippinger, et al. 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 679 691 10.1056/NEJMoa0806285 1:CAS:528:DC%2BD1MXhvVyisbk%3D 19213681
22. GK Ellis HG Bone R Chlebowski, et al. 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 4875 4882 10.1200/JCO.2008.16.3832 1:CAS:528: DC%2BD1cXhtlGitrzO 18725648
23. L Vehmanen T Saarto I Elomaa, et al. 2001 Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment Eur J Cancer 37 2373 2378 10.1016/S0959-8049(01)00317-3 1:CAS:528:DC%2BD3MXosFKgtLY%3D 11720830 (Pubitemid 33097473)
24. PD Delmas R Balena E Confravreux, et al. 1997 Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study J Clin Oncol 15 955 962 1:CAS:528:DyaK2sXitFCgs7s%3D 9060533
25. Hines SL, Mincey BA, Sloan JA, et al (2008) N02C1: a phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC) [abstract]. J Clin Oncol 26(suppl):12s (Abstr 525)
26. T Saarto L Vehmanen I Elomaa, et al. 2001 The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer Br J Cancer 84 1047 1051 10.1054/bjoc.2001.1729 1:CAS:528:DC%2BD3MXktFymur4%3D 11308252 (Pubitemid 32448500)
27. CB Confavreux A Fontana JP Guastalla, et al. 2007 Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates Bone 41 346 352 10.1016/j.bone.2007.06.004 1:CAS:528:DC%2BD2sXovFOqsbs%3D 17618847 (Pubitemid 47199159)
28. SL Greenspan A Brufsky BC Lembersky, et al. 2008 Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial J Clin Oncol 26 2644 2652 10.1200/JCO.2007.15. 2967 1:CAS:528:DC%2BD1cXnvVOhsL8%3D 18427147
29. C Van Poznak RA Hannon JR Mackey, et al. 2010 Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial J Clin Oncol 28 967 975 10.1200/JCO.2009.24.5902 20065185
30. Singh S, Cuzick J, Edwards R, et al (2007) Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II) [abstract]. Breast Cancer Res Treat 106(suppl 1):S9 (Abstr 28)
31. JE Lester D Dodwell OP Purohit, et al. 2008 Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer Clin Cancer Res 14 6336 6342 10.1158/1078-0432.CCR-07-5101 1:CAS:528:DC%2BD1cXhtF2nurbN 18829518
32. GE Fuleihan M Salamoun YA Mourad, et al. 2005 Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial J Clin Endocrinol Metab 90 3209 3214 10.1210/jc.2004-1444 (Pubitemid 41014277)
33. LS Rosen DH Gordon W Dugan Jr, et al. 2004 Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion Cancer 100 36 43 10.1002/cncr.11892 1:CAS:528:DC%2BD2cXksleksA%3D%3D 14692022 (Pubitemid 37553537)
34. Shapiro CL, Halabi S, Hars V, et al (2008) Zoledronic acid (ZA) preserves bone mineral density (BMD) in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: first results from CALBG trial 79809 [oral presentation]. Presented at 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 30 May-3 June 2008 (Abstr 512)
35. A Hoer D Gol H Gothe, et al. 2005 Rates and determinants of patient persistency with oral bisphosphonates in cancer patients [abstract] Support Care Cancer 13 428 Abstract 407-057
36. MP Ettinger R Gallagher PE MacCosbe 2006 Medication persistence with weekly versus daily doses of orally administered bisphosphonates Endocr Pract 12 522 528 17002926
37. AM Brufsky LD Bosserman RR Caradonna, et al. 2009 Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results Clin Breast Cancer 9 77 85 10.3816/CBC.2009.n.015 1:CAS:528:DC%2BD1MXmtlahtLY%3D 19433387
38. Eidtmann H, Bundred NJ, de Boer R, et al (2009) The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST [abstract]. Cancer Res 69(suppl 2):74s (Abstr 44)
39. Brufsky A, Harker WG, Beck JT, et al (2009) The effect of zoledronic acid on aromatase inhibitor-associated bone loss in premenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up [poster]. Presented at: 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 9-13 December 2009 (Abstr 4083). Available at: http://www.posters2view.com/sabcs09/viewp.php?nu=4083. Accessed 4 February 2010
40. Llombart A, Frassoldati A, Paija O, et al (2009) Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up [poster]. Presented at: ASCO 2009 Breast Cancer Symposium, San Francisco, CA, 8-10 October 2009 (Abstr 213)
41. SL Hines B Mincey T Dentchev, et al. 2009 Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC Breast Cancer Res Treat 117 603 609 10.1007/s10549-009-0332-2 1:CAS:528:DC%2BD1MXhtFegtbbI 19214743
42. Stopeck A, Body JJ, Fujiwara Y, et al (2009) Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study [oral presentation]. Presented at: ECCO 15-34th ESMO Multidisciplinary Congress; Berlin, Germany; 20-24 September 2009. Abstract 2LBA
43. Stopeck A, de Boer R, Fujiwara Y, et al (2009) A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases [abstract]. Cancer Res 69(24 suppl):490s. Abstract 422
44. MB Meads LA Hazlehurst WS Dalton 2008 The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance Clin Cancer Res 14 2519 2526 10.1158/1078-0432.CCR-07-2223 1:CAS:528:DC%2BD1cXlsV2qs74%3D 18451212
45. MC Winter I Holen RE Coleman 2008 Exploring the anti-tumour activity of bisphosphonates in early breast cancer Cancer Treat Rev 34 453 475 10.1016/j.ctrv.2008.02.004 1:CAS:528:DC%2BD1cXosVymur0%3D 18423992
46. Lin AY, Park JW, Scott J, et al (2008) Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]. J Clin Oncol 26(suppl):20s (Abstr 559)
47. B Rack C Schindlbeck B Strobl, et al. 2008 Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study Dtsch Med Wochenschr 133 285 289 10.1055/s-2008-1046707 1:CAS:528:DC%2BD1cXjtVehsbs%3D 18253918 (Pubitemid 351315392)
48. EF Solomayer G Gebauer P Hirnle, et al. 2009 Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [abstract] Cancer Res 69 suppl 2 170s 171s (Abstr 2048)
49. R Aft M Naughton K Trinkaus, et al. 2010 Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial Lancet Oncol 11 421 428 10.1016/S1470-2045(10) 70054-1 1:CAS:528:DC%2BC3cXlsFSitrw%3D 20362507
50. Zaghloul MS, Boutrus R, El-Hosieny H, et al (2008) A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients [abstract]. J Clin Oncol 26(suppl):257s (Abstr 5033)
51. A Aviles MJ Nambo N Neri, et al. 2007 Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma Med Oncol 24 227 230 10.1007/BF02698044 1:CAS:528:DC%2BD2sXpsVKlsL8%3D 17848748 (Pubitemid 350135975)
52. K Mystakidou E Katsouda E Parpa, et al. 2005 Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline Med Oncol 22 195 201 10.1385/MO:22:2:195 1:CAS:528:DC%2BD2MXos1anurc%3D 15965284 (Pubitemid 41003454)
53. D Santini B Vincenzi S Galluzzo, et al. 2007 Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients Clin Cancer Res 13 4482 4486 10.1158/1078-0432.CCR-07-0551 1:CAS:528:DC%2BD2sXotlGqtb4%3D 17671133 (Pubitemid 47219717)
54. IJ Diel A Jaschke EF Solomayer, et al. 2008 Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up Ann Oncol 19 2007 2011 10.1093/annonc/mdn429 1:STN:280:DC%2BD1cjlsFCisg%3D%3D 18664560
55. T Powles A Paterson E McCloskey, et al. 2006 Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] Breast Cancer Res 8 R13 10.1186/bcr1384 16542503 (Pubitemid 44376864)
56. Dearnaley DP, Mason MD, Parmar MK, et al (2009) Survival benefit with oral sodium clodronate in metastatic but not localised prostate cancer: Long-term results of MRC PR04 & PR05 [abstract]. Presented at ASCO 2009 Genitourinary Cancers Symposium, Orlando, FL, 26-28 February 2009 (Abstr 6)
57. T Saarto C Blomqvist P Virkkunen, et al. 2001 Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial J Clin Oncol 19 10 17 1:CAS:528:DC%2BD3MXot1Whuw%3D%3D 11134190
58. E Bria C Nistico F Cuppone, et al. 2006 Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients Cancer 106 2337 2344 10.1002/cncr.21886 1:CAS:528:DC%2BD28Xls1Srur0%3D 16649217 (Pubitemid 43787656)
59. RE Coleman MC Winter D Cameron, et al. 2010 The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer Br J Cancer 102 1099 1105 10.1038/sj.bjc.6605604 1:CAS:528:DC%2BC3cXjvFymtr0%3D 20234364
60. Coleman R, Bundred NJ, De Boer R, et al (2009) Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST [poster]. Presented at 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 9-13 December 2009 (Abstr 4082). Available at: http://www.posters2view.com/sabcs09/viewp.php?nu=4082. Accessed 3 February 2010
61. BE Hillner JN Ingle RT Chlebowski, et al. 2003 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 4042 4057 10.1200/JCO.2003.08.017 1:CAS:528:DC%2BD2cXpsVajsbY%3D 12963702 (Pubitemid 46606220)
62. P Hadji JJ Body MS Aapro, et al. 2008 Practical guidance for the management of aromatase inhibitor-associated bone loss Ann Oncol 19 1407 1416 10.1093/annonc/mdn164 1:STN:280:DC%2BD1cvotVOrsA%3D%3D 18448451
63. DM Reid J Doughty R Eastell, et al. 2008 Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group Cancer Treat Rev 34 suppl 1 S3 S18 10.1016/j.ctrv.2008.03.007 1:CAS:528:DC%2BD1cXmvVOnsrs%3D 18515009